Coffee drinking linked to lower subclinical atherosclerosis

04.03.20151854
Light to moderate coffee drinking – less than 5 cups per day – is associated with decreased coronary artery calcium, and thus decreased risk of cardiovascular disease, according to an analysis of a large cohort published online March 2 in Heart.

Study: No benefit from anticoagulant use in Beh?et’s disease

03.03.20151323
Patients with vascular manifestations of Beh?et’s disease who received treatment with anticoagulants did not benefit from the therapy given in addition to immunosuppressant drugs, according to results from study of practices in Turkish rheumatology clinics.

Boehringer Ingelheim files BLA for antidote to dabigatran

02.03.20151395
Boehringer Ingelheim announced that it has submitted a biologics license application to the FDA requesting an accelerated approval pathway for idarucizumab, an antidote to dabigatran.

Serious cardiac complications in coronary spasm provocation tests using acetylcholine or ergonovine: analysis of 21 512 patients from the diagnosis procedure combination database in Japan

28.02.20151589
This retrospective cohort study suggested that acetylcholine (ACH) tests were associated with a higher rate of cardiac complications than ergonovine (ER) tests.

Statin use may reduce risk for liver cancer

27.02.20151324
The use of statins decreased the risk for primary liver cancer, especially in patients with liver disease and diabetes, according to newly published data.

Larger and more severe strokes seen with aspirin resistance

25.02.20151746
Patients with acute ischemic stroke who test positive for aspirin resistance had both larger stroke volume and increased severity, compared with patients without resistance, in an observational study of 311 patients at Korean centers.

Concomitant NSAIDs with antithrombotic therapy after MI worsen outcomes

24.02.20151485
In a study of patients assigned antithrombotic therapy after MI, concomitant use of nonsteroidal anti-inflammatory drugs were associated with increased risk for bleeding and excess thrombotic events, regardless of treatment duration.
Данный сайт и вся информация на нём предназначена для медицинских работников. Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.